Hormone Therapy Research for Cardiometabolic Risk

Investigate the impact of hormone therapy on vasomotor symptoms and its link to cardiometabolic risk factors.

Abstract

In this educational post, I share a clear, first-person journey through the physiology, diagnosis, and treatment of vasomotor symptoms of menopause. I detail why hot flashes and night sweats occur, summarize the menopausal transition using modern, evidence-based frameworks, and explain how targeted therapies—hormone therapy, neurokinin B antagonism, SSRIs/SNRIs, and lifestyle interventions—align with the latest research. I introduce our clinic’s multidisciplinary structure, including medical direction by Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), and my role as an integrative chiropractic and functional medicine practitioner. Together, we provide comprehensive plans that include medical oversight, musculoskeletal rehabilitation, autonomic and sleep optimization, nutrition, and personal injury care, while prioritizing safety, shared decision-making, and clinical outcomes. This post also highlights how the integrative, multidisciplinary model at Injury Medical Clinic PA in El Paso, Texas, brings together chiropractic care, internal medicine, functional medicine, and rehabilitation to deliver whole-person, patient-centered women’s health care. I include clinical observations from my work, supported by evidence and practical protocols for primary care readers.

Introduction: Who We Are and How We Care

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we operate within a multidisciplinary, integrative model that blends chiropractic medicine, functional medicine, rehabilitation, and personal injury care under medical direction. My clinical work and published observations are available at wellnessdoctorrx.com and on my LinkedIn professional profile.

• Medical leadership: Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933) serves as our Medical Director and Collaborative Physician. With over 40 years of experience in internal medicine, Dr. Cardenas provides medical oversight, diagnostic support, risk stratification, prescription management (including menopause-related therapies), and care coordination for complex cases.
• Integrative chiropractic care: I lead biomechanical assessment, spinal and extremity adjustments, neuromuscular rehabilitation, autonomic balance strategies, and non-pharmacologic pain management.
• Functional medicine and rehabilitation: We coordinate nutrient, metabolic, and inflammatory assessments; sleep and stress interventions; pelvic health referrals; and structured exercise and physical therapy programs.
• Personal injury care: We integrate acute trauma rehabilitation, imaging, impairment reviews, and return-to-function plans, recognizing that injuries and pain can amplify vasomotor symptoms via stress and autonomic dysregulation.

My goal here is to make the latest evidence on menopause simple to understand and actionable for primary care and integrative clinicians—and for patients who want clarity.

Understanding Vasomotor Symptoms: A Patient-Centered Start

When a patient like Jenny, a 52-year-old scientist, sits with me, she describes waking “wrapped in a hot blanket,” drenched, and exhausted. She asks, “Why is this happening?” Will it go away? What can we do now? One of the most common questions I hear is simply: “Am I going to deal with this until I die? Or can I actually do something to decrease these hot flashes?”

I start with physiology, then build a plan together. Shared decision-making is central. Many women feel unheard; we correct that by linking symptoms to mechanisms and options.

Key Learning Objectives

• Identify and summarize the definition and timeline of vasomotor symptoms
• Examine hormonal physiology and stages of menopause
• Build assessment, diagnosis, and medical management strategies for vasomotor symptoms
• Individualize treatment plans with emphasis on hormonal agents and integrative options

Menopause Definitions, Timelines, and Staging: The Roadmap

 

• Menopause is defined as the final menstrual period followed by 12 months of amenorrhea, reflecting loss of follicular function and declining ovarian hormone production (Edelman et al., 2023).
• Typical onset: Ages 45–55; median age in the U.S. ~52.5 years. Early menopause occurs before 45; premature menopause before 40 (Parmar et al., 2023).
• Systems affected: Beyond genitourinary changes, we see shifts across cardiovascular, skeletal, neurological, and metabolic systems due to estrogen decline, stress axis perturbations, and immune/inflammatory modulation.

Evidence-Based Staging Frameworks

• The Stages of Reproductive Aging Workshop (STRAW+10) provides standardized criteria for reproductive, menopausal transition, and postmenopausal phases based on cycle changes and supportive biomarkers (Harlow et al., 2012).
• Menopausal transition:

• • Early: cycle length variability ≥7 days from usual
  • Late: amenorrhea episodes ≥60 days; fluctuating FSH generally rising; estradiol declines

• Postmenopause:

• • Early: first years after final period; vasomotor symptoms (VMS) most common
  • Late: VMS often diminish but may persist for years in many women

Why we use this framework: STRAW+10 helps clinicians align symptoms with physiological patterns, governs lab interpretation (especially FSH variability), and improves counseling about expected trajectories.

Hormone Physiology: Why Hot Flashes Happen

The menopausal transition is a symphony of shifting signals across the hypothalamic-pituitary-ovarian (HPO) axis, the thermoregulatory network, and peripheral tissues.

Core Hormonal Changes

• Inhibin drops: Ovarian inhibin normally suppresses pituitary FSH. Declines in inhibin release disinhibit FSH—FSH rises (Burger et al., 2002).
• FSH fluctuates widely: Elevated trends with significant day-to-day variability during transition; high FSH no longer reliably stimulates estradiol due to depleted follicles.
• Estradiol (E2) levels fall: After menopause, estrone (E1) predominates via peripheral conversion in adipose and adrenal tissues; E2 typically declines below ~10 pg/mL (Santoro & Randolph, 2011).
• Progesterone lowers: Less frequent ovulation means reduced luteal progesterone, contributing to cycle irregularity and sleep changes.
• Testosterone usually decreases modestly but may remain within reference ranges; DHEA/DHEAS changes are variable and age-related more than menopause-specific (Davison et al., 2005).

Thermoregulation and Neuroendocrine Drivers of VMS

• Thermoneutral zone narrowing: The hypothalamus normally buffers minor fluctuations in body temperature. With estrogen decline, that zone narrows; small internal/external triggers provoke outsized heat-dissipation responses—peripheral vasodilation and diaphoresis—felt as hot flashes (Freedman, 2014).
• KNDy neuron network: Hypothalamic neurons co-express kisspeptin, neurokinin B (NKB), and dynorphin. Estrogen normally inhibits NKB-driven activation of KNDy neurons. With low estrogen, unopposed NKB stimulation increases, destabilizing heat regulation and LH pulsatility—closely associated with hot flash events (Middleton et al., 2022).
• Autonomic arousal and sleep disruption: VMS are often nocturnal; sympathetic activation, microarousals, and sweating lead to fragmented sleep, worsening pain perception, mood, and insulin resistance (Carroll et al., 2017).

Clinical Observations From Practice

At Injury Medical Clinic PA, I see that:

• Patients with a higher baseline stress load, chronic pain, or injury-related sympathetic overdrive experience more frequent and severe VMS.
• Correcting sleep debt and autonomic imbalance (breathing drills, vagal tone exercises, cervical/thoracic biomechanical correction) reduces VMS intensity for many, even before pharmacologic treatments.
• In women with higher adiposity, evening hot flashes are more pronounced, likely due to thermoregulation, inflammation, and estrogen metabolism. Structured exercise and anti-inflammatory nutrition help meaningfully.

Symptoms and Risks: What Patients Experience

Common VMS and Related Menopausal Features

• Hot flashes and night sweats
• Sleep disturbances, anxiety, and mood changes
• Genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, urinary urgency, recurrent infections
• Metabolic slowing, weight gain, skin and hair changes
• Musculoskeletal pain and joint stiffness
• Cognitive complaints and memory lapses
• Cardiometabolic risks: observational links between severe, prolonged VMS and cardiovascular disease risk profiles; ethnic differences in duration and severity—African American women may report longer persistence (Avis et al., 2015).

Why Diagnosis Is Clinical First

• For women in typical age ranges (around 50–55) with consistent cycle history and symptoms, menopause is largely a clinical diagnosis—no lab test is required to confirm (The Menopause Society, 2023).
• FSH and estradiol testing can be informative in premature or atypical cases, but variability limits reliability. Decisions should be individualized with shared decision-making.
• Labs are most useful for ruling out mimics (thyroid disorders, infection, hematologic issues), assessing cardiometabolic risk, and informing broader care plans (lipids, A1c, ferritin, vitamin D).

---

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

---

Our Multidisciplinary Model: Integrative Care with Medical Direction

This is where our team-based approach ensures patients receive thorough, coordinated care that addresses the full spectrum of their health needs, not just isolated symptoms.

How We Integrate

• Medical direction and safety: Cardenas oversees prescription therapies (including menopausal hormone therapy and non-hormonal agents), screens for contraindications, manages comorbidities, and tracks longitudinal outcomes.
• Chiropractic integration: I evaluate spinal and rib mobility, thoracic mechanics affecting breathing, and implement adjustments, soft-tissue care, and autonomic-balancing techniques that reduce nociception and sympathetic drive.
• Functional medicine: We examine nutrition, gut health, and inflammation, and craft evidence-informed strategies for weight management, glycemic balance, and micronutrient repletion that influence thermoregulation.
• Rehabilitation: Structured exercise therapy, diaphragmatic breathing, and postural restoration improve heat dissipation efficiency, sleep quality, and pain resilience.
• Personal injury care: Trauma and chronic pain elevate stress hormones. By resolving biomechanical loads and inflammatory drivers, VMS severity often declines.

Treatment Options for Menopausal Symptoms: Evidence-Based, Personalized

Treatment for menopausal symptoms can be organized into four primary categories. We match therapies to physiology and risk profile, guided by safety, efficacy, and patient values.

Hormone Therapy for VMS

• Systemic estrogen therapy is the most effective treatment for moderate-to-severe VMS in appropriate candidates (The Menopause Society, 2023).

• • Formulations: Transdermal estradiol patches/gels minimize first-pass hepatic effects and may carry lower VTE risk compared with oral preparations.
  • Add progestogen for women with an intact uterus to prevent endometrial hyperplasia (micronized progesterone or levonorgestrel IUD).

• Rationale: Restoring estrogen expands the thermoneutral zone, stabilizes KNDy neuron activity, and improves sleep and mood.
• Timing and risk: The window of opportunity—within 10 years of menopause onset and before age 60—may optimize benefit-risk, with careful screening for VTE, stroke, breast cancer, coronary disease, and migraine (Manson et al., 2013).
• Monitoring: Blood pressure, lipids, breast health screening, endometrial surveillance if indicated. Use the lowest effective dose, reassess periodically, and individualize duration.

Non-Hormonal Pharmacologic Options

• SSRIs/SNRIs: Paroxetine 7.5 mg, venlafaxine, escitalopram reduce hot flash frequency and severity by modulating serotonergic thermoregulation (Shifren & Gass, 2014).
• Gabapentin: Effective for nocturnal VMS and sleep improvement.
• Fezolinetant: A selective neurokinin-3 receptor antagonist that directly targets NKB-KNDy pathways, demonstrating significant VMS reduction without hormones (Fraser et al., 2023). Rationale: It blunts NKB-driven hypothalamic activation underlying hot flashes.
• Selection: Non-hormonal strategies are preferred when hormone therapy is contraindicated or declined.

Non-Pharmacological and Complementary Therapies

• Cognitive Behavioral Therapy (CBT): More effective at reducing the severity of hot flashes than their frequency, but limited provider availability and costs are barriers (Ayers et al., 2012).
• Clinical Hypnosis: An emerging intervention showing significant reductions in hot flash frequency and severity, but provider scarcity and cost are also limitations (Elkins et al., 2013).

Lifestyle, Nutrition, and Functional Strategies

• Weight management and exercise: reduce inflammation and improve heat regulation; aerobic plus resistance training show consistent benefits.
• Sleep optimization: CBT-I, sleep hygiene, a cool bedroom environment; magnesium glycinate may improve sleep quality.
• Stress modulation: Mindfulness, paced breathing (e.g., 4-6 breaths per minute), and HRV training improve autonomic balance.
• Dietary pattern: Emphasize anti-inflammatory foods, adequate protein, and phytoestrogen-rich foods (e.g., soy); monitor intake of alcohol and spicy foods if they trigger VMS.
• Micronutrients: Vitamin D, omega-3s, and magnesium support musculoskeletal comfort, mood, and cardiometabolic health. A robust nutritional base stabilizes systemic physiology.

The Role of Integrative Chiropractic Care in Menopause Management

While chiropractic care does not directly replace hormonal therapy, it addresses several critical physiological domains that influence menopausal health.

Why Chiropractic Belongs In This Plan

• Thoracic spine and rib function: Improved mobility facilitates more efficient breathing mechanics, supporting heat loss and reducing sympathetic tone spikes during VMS events.
• Cervical and upper thoracic adjustments: Can decrease nociceptive drive to the spinal cord, alleviating muscle tension that exacerbates perceived heat and anxiety during flashes.
• Soft tissue release: Pectoral, scalene, and suboccipital care improves respiratory efficiency and vagal tone.
• Autonomic strategies: Gentle cranial and cervical techniques, combined with paced breathing, reduce sympathetic overactivity, which often compounds night sweats.
• HPA Axis Support and Stress Reduction: The hypothalamic-pituitary-adrenal (HPA) axis is intimately connected to the menopausal transition. Chiropractic care, combined with functional medicine interventions addressing adrenal fatigue, gut health, and inflammatory load, provides a physiological environment more conducive to hormonal equilibrium.
• Musculoskeletal Health and Osteoporosis Prevention: Menopause accelerates bone density loss. Chiropractic care, combined with targeted rehabilitation and weight-bearing exercise protocols, supports bone health, postural integrity, and balance, reducing fracture risk.

Clinical Reasoning

VMS are mediated centrally but amplified by peripheral factors: pain, sleep fragmentation, inflammation, and stress. When we reduce biomechanical stress and nervous system arousal, patients report fewer and less intense VMS episodes. Our observations match research linking autonomic balance and sleep quality to hot flash burden.

Individualizing Care: Building a Shared Plan with Jenny

For a 52-year-old postmenopausal patient with severe night sweats:

• Assess:

• • History: Cycle timeline, VMS frequency, triggers, sleep pattern, mood symptoms, vaginal symptoms, sexual function.
  • Risks: VTE, stroke, breast cancer, cardiovascular disease, migraines with aura, liver health, smoking.
  • Labs: Targeted—TSH, fasting lipids, A1c if indicated; consider ferritin and vitamin D.

• Decide:

• • If low risk and within 10 years of menopause: consider transdermal estradiol plus micronized progesterone (if uterus present).
  • If hormone therapy is not preferred or contraindicated: consider fezolinetant, SSRI/SNRI, or gabapentin.

• Integrate:

• • Chiropractic: Thoracic/cervical adjustments, rib mobilization, diaphragm mechanics.
  • Rehabilitation: Daily brisk walking, resistance training 2–3x/week.
  • Sleep and stress: CBT-I referral, breath training at bedtime.
  • Nutrition: High-fiber, phytonutrient-rich diet; reduce alcohol if triggering.
  • GSM care: Local vaginal estrogen for dryness if present.

Safety, Oversight, and Follow-Up in Our Clinic

Under Dr. Cardenas’s medical direction, we maintain rigorous safety protocols.

• We review contraindications, adjust medications, and monitor side effects. For hormone therapy, we track blood pressure, weight, and symptom scores; schedule regular breast screening and discuss endometrial health.
• For non-hormonal agents, we monitor mood, sleep, blood pressure, and liver parameters when indicated (e.g., for fezolinetant).
• We set clear re-evaluation points at 8–12 weeks to measure VMS frequency, sleep quality, and functional outcomes.

Our Day-to-Day Workflow

• Initial consults: I assess musculoskeletal and autonomic factors; Dr. Cardenas reviews medical risks and pharmacologic options; we co-create a plan.
• Coordinated interventions: We combine safe medication strategies with hands-on care, exercise prescriptions, and nutrition planning.
• Follow-up cadence: 4–6 weeks for initial reassessment, then ongoing intervals tailored to symptom reduction and risk monitoring.

Conclusion: Confident, Evidence-Based Relief Is Possible

Managing menopause effectively demands more than selecting a single medication. It requires an individualized, multidisciplinary approach that respects the full complexity of each woman’s physiology, history, values, and goals. Vasomotor symptoms emerge from a sophisticated interplay of hormone decline and hypothalamic thermoregulation. They are common, disruptive, and treatable. Our integrative model—combining medical oversight by Dr. Maria Guadalupe Cardenas, MD, with chiropractic care, functional medicine, rehabilitation, and personal injury support—offers a structured, safe path to relief. We combine the clinical depth of internal medicine with the holistic approaches of chiropractic care, functional medicine, rehabilitation, and advanced practice nursing to offer women a comprehensive, evidence-informed path through the menopausal transition—not just symptom management, but genuine restoration of vitality and well-being.

If you are experiencing night sweats or hot flashes that disrupt your life, we can help you navigate a modern, evidence-based plan designed for your unique physiology and goals.

References

• Avis, N. E., Crawford, S. L., et al. (2015). Hot flashes and cardiovascular risk. Circulation, 132(25), 2338–2345.
• Ayers, B., Smith, M., Hellier, J., Mann, E., & Hunter, M. S. (2012). Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): A randomized controlled trial. Menopause, 19(7), 749- 759.
• Burger, H. G., Hale, G. E., et al. (2002). Inhibin and FSH dynamics in menopause. Human Reproduction, 17(12), 3274–3281.
• Carroll, J. E., Irwin, M. R., et al. (2017). Sleep disruption and vasomotor burden. Sleep Medicine Reviews, 31, 70–78.
• Davison, S. L., Bell, R., et al. (2005). Androgen and DHEA changes with aging. Journal of Clinical Endocrinology & Metabolism, 90(7), 3847–3853.
• Elkins, G. R., Fisher, W. I., Johnson, A. K., Carpenter, J. S., & Keith, T. Z. (2013). Clinical hypnosis in the treatment of postmenopausal hot flashes: A randomized controlled trial. Menopause, 20(3), 291- 298.
• Fraser, G. L., Lederman, S., et al. (2023). Fezolinetant efficacy for moderate-to-severe vasomotor symptoms. New England Journal of Medicine, 388, 2093–2104.
• Freedman, R. R. (2014). Menopausal hot flashes: Mechanisms, endocrinology, treatment. Journal of Steroid Biochemistry and Molecular Biology, 142, 115- 120.
• Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., et al. (2012). STRAW+10: Staging System for Reproductive Aging revisited. Human Reproduction Update, 18(1), 58–69.
• Manson, J. E., Chlebowski, R. T., et al. (2013). Menopausal hormone therapy and chronic disease risk: Timing hypothesis. JAMA, 310(13), 1353–1368.
• Middleton, L. J., Nazarian, S., et al. (2022). KNDy neurons and vasomotor symptoms: neuroendocrine underpinnings. Nature Reviews Endocrinology, 18, 681–692.
• The Menopause Society. (2023). The 2023 Menopause Society position statement on hormone therapy.
• Santoro, N., & Randolph, J. F. Jr. (2011). Hormone changes across the menopausal transition. Journal of Clinical Endocrinology & Metabolism, 96(2), 346–355.
• Shifren, J. L., & Gass, M. L. S. (2014). Management of symptomatic vulvovaginal atrophy: NAMS position. Menopause, 21(10), 1063–1068.

SEO Tags:

menopause vasomotor symptoms, hot flashes night sweats, KNDy neurons neurokinin B, fezolinetant NK3R antagonist, hormone therapy menopause, transdermal estradiol safety, SSRIs SNRIs hot flashes, chiropractic care menopause, integrative functional medicine menopause, El Paso Injury Medical Clinic, Dr Alex Jimenez DC APRN FNP-BC, Dr Maria Guadalupe Cardenas MD Medical Director, STRAW+10 staging menopause, thermoneutral zone hypothalamus, genitourinary syndrome of menopause, sleep optimization VMS, autonomic regulation chiropractic, personal injury and menopause, menopause treatment El Paso, estrogen therapy options, transdermal estrogen patch, estrogen gel menopause, non-hormonal menopause treatment, integrative menopause care, functional medicine women’s health, progesterone therapy menopause, Mission Plaza Injury Medical Clinic, multidisciplinary women’s health care, perimenopause treatment options, FDA approved hormone therapy, CBT for hot flashes, NK3 receptor antagonist menopause, bioidentical hormones, menopause integrative care, SERM menopause therapy, estradiol cypionate menopause, women’s health El Paso Texas